University of Sydney Institutional Biosafety Committee

This form is to be completed by the Principal Investigator and must be submitted by the Principal
Investigator
Name of Principal Investigator:
Project title:
Type of project proposal:
□ Exempt Dealing
□ NLRD
□ DNIR
RIMS Project ID Code: (for projects that are part of a funded research grant )

For completion by IBC.
IBC Reference Number
Name of IBC Chair
Prof Anthony Weiss
Signature
Exempt Dealing application form – July 2014
Date of approval
Page 1
University of Sydney Institutional Biosafety Committee – Exempt Dealing
application form
1. Exemption Category – Please place an X in the appropriate box/s
OGTR Mark
Item # with
an X
2
Description of Dealing
A dealing with a genetically modified Caenorhabditis elegans,
whereby:
a) an advantage is not conferred on the animal by the genetic
modification; and
b) as a result of the genetic modification, the animal is not capable of
secreting or producing an infectious agent.
3
A dealing with an animal into which genetically modified somatic
cells have been introduced, if:
a) the somatic cells are not capable of giving rise to infectious agents
as a result of the genetic modification; and
b) the animal is not infected with a virus that is capable of
recombining with the genetically modified nucleic acid in the
somatic cells.
3A
A dealing with an animal whose somatic cells have been genetically
modified in vivo by a replication defective viral vector, if:
a) the in vivo modification occurred as part of a previous dealing;
and
b) the replication defective viral vector is no longer in the animal;
and
c) no germ line cells have been genetically modified; and
d) the somatic cells cannot give rise to infectious agents as a result of
the genetic modification; and
e) the animal is not infected with a virus that can recombine with the
genetically modified nucleic acid in the somatic cells of the animal.
Exempt Dealing application form – July 2014
Page 2
4
1) Subject to subitem 2) below, a dealing involving a host/vector
system mentioned in Part 2 of Schedule 2 and producing no more
than 25 litres of GMO culture in each vessel containing the resultant
culture.
2) The donor nucleic acid:
a) must meet either of the following requirements:
i) it must not be derived from organisms implicated in, or with a
history of causing, disease in otherwise healthy human beings,
animal, plants or fungi;
ii) it must be characterised and the information derived from its
characterisation show that it is unlikely to increase the capacity of
the host or vector to cause harm; and
b) must not code for a toxin with an LD50 of less than 100µg/kg; and
c) must not code for a toxin with an LD50 of 100µg/kg or more, if the
intention is to express the toxin at high levels; and
d) must not be uncharacterised nucleic acid from a toxin-producing
organism; and
e) must not include a viral sequence, unless the donor nucleic acid:
i) is missing at least 1 gene essential for viral multiplication that:
A) is not available in the cell into which the nucleic acid is
introduced; and
B) will not become available during the dealing; and
ii) cannot restore replication competence to the vector.
5
A dealing involving shot-gun cloning, or the preparation of a cDNA
library, in a host/vector system mentioned in item 1 of Part 2 of
Schedule 2, if the donor nucleic acid is not derived from either:
a) a pathogen; or
b) a toxin-producing organism.
2. Name and full professional address of Principal Investigator submitting proposal
Name:
Department:
Room No:
Building Name:
Tel:
Email:
3. Name(s) of other Principal Investigators responsible for the project. Please provide
their professional addresses if different from that above.
Exempt Dealing application form – July 2014
Page 3
4. Describe the aim of the work
5. Describe the main experimental procedures of the work
6. Details of biological system
Note: Any substantial change in the system will require submission of another
proposal
(a) Describe the biological source of the donor DNA to be used – include the genus,
species and strain or organ/tissue as applicable. Include the specific genes to be
involved in the dealing.
(b) Describe the host organism or tissue to be used – include the genus, species and
strain where applicable. If not a commonly used laboratory strain, include the name
of the strain from which it is derived.
(c) Describe the vectors or methods to be used to transfer donor DNA to the host.
Include information regarding the origin and properties of the vector and confirm that
all bacterial plasmid vectors are non-conjugative. If your project involves the use of a
replication defective viral vector (unable to transduce human cells), please provide an
explicit description of the assay you intend to perform to exclude the presence of
replication competent virus.
Exempt Dealing application form – July 2014
Page 4
7. If you believe the protein/gene is characterised, and unlikely to increase the
capacity of the host or vector to cause harm, briefly explain why, referring to what is
known about its structure, function and/or genetics.
8. Does the DNA encode a toxin?
□ Yes
□ No
If yes, please provide the LD50
9. Where will this work be conducted? Please provide Room Number, Building
Name and Building Code.
10. Do you have approval to use this facility?
Yes [
]
No [
]
11. Proposed date of commencement of work.
12. Likely duration of work.
13. Signature of Principal Investigator submitting this proposal.
Date
Exempt Dealing application form – July 2014
/
/
Page 5